On August 30th, 2017, the German Regulatory Drug and Medical Device Agency, BfArM, has granted a special approval to the wound healing device LeiProtect®, developed by our NPO, Waisenmedizin e. V., to treat CL wounds after its painless application. This allows us to produce 60 kg of LeiProtect® to treat approximately 6,000 patients during the upcoming leishmania season.
We have already pre-financed the good manufacturing production (GMP) of 10 kg of LeiProtect® worth 9,350 € for Leishmaniasis patients in Syria and Algeria. We need funds to fully utilize the special BfArM approval.
Our medical aid is an essential contribution to peace in previously war torn countries coming from Europe. Every two euros you can spare helps cure one poor leishmaniasis patient and allows Europe to implement her founding idea as a peace searching state community.
Fifteen years of medical aid towards neglected diseases in Afghanistan have given us a distinctive competence in this domain and has created a network of trustworthy partners on-site for medical help in leishmania endemic countries.
To visit our Betterplace campaign, please click the button below.